Comparison of Visceral Adipokines Visfatin, Vaspin and Omentin Levels in Gestational Diabetes Mellitus Pregnant Women

The Relation Between Visceral Adipokines Gestational Diabetes Mellitus

The prevalence of maternal obesity is increasing rapidly worldwide and constitutes an important obstetric problem that increases mortality and morbidity in both mothers and infants. Obese women are prone to pregnancy complications such as gestational diabetes mellitus (GDM), and children of obese mothers are more likely to develop cardiovascular and metabolic disease later in life. The risk of developing GDM in obese pregnants is 1.3-3.8 times higher than in pregnant women with a normal body mass index, and approximately 70% of women with GDM remain at risk of developing type 2 diabetes until 28 years postpartum. Gestational diabetes mellitus (GDM) affects approximately 6% of pregnant women and its prevalence is increasing in parallel with the obesity epidemic. GDM is associated with an increased risk of adverse pregnancy outcomes, including macrosomia, preterm delivery, neonatal hypoglycemia, neonatal jaundice, and congenital anomalies. It is also associated with a higher incidence of type 2 diabetes mellitus after birth. It is known that visceral adipose tissue increases in obese women. It is thought that there is a relationship between visceral adipose tissue increase and diabetes. In this study, the levels of new adipocytokines such as Visfatin, Vaspin and Omentin secreted from visceral adipose tissue in patients diagnosed with GDM will be measured.

Study Overview

• Status: Completed
• Conditions: Obesity; Gestational Diabetes; Visceral Obesity
• Intervention / Treatment: Diagnostic test: oral glucose tolerance test; Diagnostic test: Blood sample

Detailed Description

The investigators aim in this study the levels of Visfatin, Vaspin and Omentin secreted from this tissue in pregnant women diagnosed with GDM by oral glucose tolerance test (OGTT) between 24-28 weeks of gestation and to determine if there is a relationship between these parameters. For this purpose, , and 87 pregnant women with gestational diabetes diagnosed at 24-28 weeks from the same patient group will be included in the study. . The same number of non-GDM control group pregnant women will also be included in the study at 24-28 weeks. Age, gestational week, pregnancy history (gravida, parity, abortion, missed, ectopic), medical history, preconceptional BMI, current BMI, triglyceride, VLDL, HDL, LDL, cholesterol, HOMA-IR, C-peptide, insulin, Hba1c levels will be saved. In the 2nd trimester, between 24-26 weeks, OGTT will be performed on the patients and the results will be recorded. Visfatin, Vaspin and Omentin levels will be checked and recorded in patients diagnosed with GDM.

• Study Type: Observational
• Enrollment (Actual): 174

Contacts and Locations

Study Locations

• Turkey
  • Siirt, Turkey, 56000
    • Siirt Üniversity Medical Faculty

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

Pregnant women over the age of 18 who are in the first trimester of pregnancy and are not diagnosed with diabetes

Description

Inclusion Criteria:

• >18 years of age
• At the 2.st trimester of pregnancy

Exclusion Criteria:

• History of with diabetes mellitus
• Morbidly obese pregnants
• History of abdomen liposuction

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Pregnant women with gestational diabetes(n:87); Visceral adipokine level will be examined in pregnant women with gestational diabetes.	Diagnostic test: oral glucose tolerance test; oral glucose tolerance test (OGTT) used for the diagnosis of gestational diabetes mellitus between 24-28 weeks of gestation; Diagnostic test: Blood sample; Measurement of blood Visfatin, Vaspin and Omentin levels in pregnant women with diabetes
Control group pregnant (n:87); Visceral adipokine level will be examined in pregnant women with normal pregnant .	Diagnostic test: oral glucose tolerance test; oral glucose tolerance test (OGTT) used for the diagnosis of gestational diabetes mellitus between 24-28 weeks of gestation; Diagnostic test: Blood sample; Measurement of blood Visfatin, Vaspin and Omentin levels in pregnant women with diabetes

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
24-28. Visceral Adipokine Levels in Pregnant Women with Gestational Diabetes Between Weeks	VASPIN, VISFATIN, OMENTIN levels will be measured in patients with gestational diabetic,	Between 24-28 weeks of pregnancy, (an average of 6 months)

Collaborators and Investigators

• Sponsor: Siirt University
• Investigators: Study Director: Şerif Aksin, Siirt Üniversity Medical Faculty Obstetrics and Gynecology Department; Study Director: Şerif Aksin, Assoc.Prof, Siirt University Medical Faculty Obstetrics and Gynecology Departmant

Study record dates

Study Major Dates

• Study Start (Actual): October 31, 2022
• Primary Completion (Actual): August 25, 2023
• Study Completion (Actual): August 25, 2023

Study Registration Dates

• First Submitted: June 30, 2022
• First Submitted That Met QC Criteria: July 14, 2022
• First Posted (Actual): July 18, 2022

Study Record Updates

• Last Update Posted (Actual): August 28, 2023
• Last Update Submitted That Met QC Criteria: August 24, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Overnutrition; Nutrition Disorders; Overweight; Body Weight; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Diabetes Mellitus; Obesity; Obesity, Abdominal; Diabetes, Gestational
• Other Study ID Numbers: SiirtUNI

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No